Makena (autoinjector) Patent Expiration

Makena (autoinjector) is a drug owned by Covis Pharma Gmbh. It is protected by 13 US drug patents filed from 2018 to 2022. Out of these, 12 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 02, 2036. Details of Makena (autoinjector)'s patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154562 Methods of reducing risk of preterm birth
May, 2036

(11 years from now)

Active
US10471075 Methods of reducing risk of preterm birth
May, 2036

(11 years from now)

Active
US9844558 Methods of reducing risk of preterm birth
May, 2036

(11 years from now)

Active
US11304962 Methods of reducing risk of preterm birth
May, 2036

(11 years from now)

Active
US9789257 Needle assisted injection device having reduced trigger force
Feb, 2034

(9 years from now)

Active
US11446440 Needle assisted injection device having reduced trigger force
Aug, 2031

(6 years from now)

Active
US8021335 Prefilled syringe jet injector
Oct, 2026

(1 year, 10 months from now)

Active
US9533102 Prefilled syringe jet injector
Jan, 2026

(1 year, 2 months from now)

Active
US9180259 Prefilled syringe jet injector
Jan, 2026

(1 year, 2 months from now)

Active
US9629959 Prefilled syringe jet injector
Jan, 2026

(1 year, 2 months from now)

Active
US8562564 Prefilled syringe jet injector
Jan, 2026

(1 year, 2 months from now)

Active
US11446441 Prefilled syringe injector
Jan, 2026

(1 year, 2 months from now)

Active
USRE44846 Needle assisted jet injector
Aug, 2019

(5 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Makena (autoinjector)'s patents.

Given below is the list of recent legal activities going on the following patents of Makena (autoinjector).

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 01 Jul, 2024 US9533102
Expire Patent 18 Dec, 2023 US10471075
Maintenance Fee Reminder Mailed 03 Jul, 2023 US10471075
Payment of Maintenance Fee, 8th Year, Large Entity 08 May, 2023 US9180259
Payment of Maintenance Fee, 12th Year, Large Entity 16 Mar, 2023 US8021335
Patent Issue Date Used in PTA Calculation 20 Sep, 2022 US11446440
Recordation of Patent Grant Mailed 20 Sep, 2022 US11446440
Recordation of Patent Grant Mailed 20 Sep, 2022 US11446441
Patent Issue Date Used in PTA Calculation 20 Sep, 2022 US11446441
Email Notification 01 Sep, 2022 US11446441

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Makena (autoinjector)'s European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Makena (autoinjector)'s generic, the next section provides detailed information on ongoing and past EP oppositions related to Makena (autoinjector) patents.

Makena (autoinjector)'s Oppositions Filed in EPO

Makena (autoinjector) has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 07, 2019, by Bandpay & Greuter. This opposition was filed on patent number EP06719329A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP19150366A Sep, 2022 Bandpay & Greuter Granted and Under Opposition
EP06719329A Oct, 2019 Bandpay & Greuter Patent maintained as amended


US patents provide insights into the exclusivity only within the United States, but Makena (autoinjector) is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Makena (autoinjector)'s family patents as well as insights into ongoing legal events on those patents.

Makena (autoinjector)'s Family Patents

Makena (autoinjector) has patent protection in a total of 13 countries. It has a significant patent presence in the US with 61.9% of its patents being US patents. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Makena (autoinjector).

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Makena (autoinjector)'s generic launch date based on the expiry of its last outstanding patent is estimated to be May 02, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Makena (autoinjector) Generic API suppliers:

Hydroxyprogesterone Caproate is the generic name for the brand Makena (autoinjector). 6 different companies have already filed for the generic of Makena (autoinjector), with Eugia Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Makena (autoinjector)'s generic

How can I launch a generic of Makena (autoinjector) before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Makena (autoinjector)'s patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Makena (autoinjector)'s sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Makena (autoinjector) -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
275 mg/1.1 mL 28 Sep, 2020 1 02 May, 2036





About Makena (autoinjector)

Makena (Autoinjector) is a drug owned by Covis Pharma Gmbh. It is used for reducing the risk of preterm birth in women with a history of singleton spontaneous preterm birth. Makena (Autoinjector) uses Hydroxyprogesterone Caproate as an active ingredient. Makena (Autoinjector) was launched by Covis in 2018.

Approval Date:

Makena (autoinjector) was approved by FDA for market use on 14 February, 2018.

Active Ingredient:

Makena (autoinjector) uses Hydroxyprogesterone Caproate as the active ingredient. Check out other Drugs and Companies using Hydroxyprogesterone Caproate ingredient

Treatment:

Makena (autoinjector) is used for reducing the risk of preterm birth in women with a history of singleton spontaneous preterm birth.

Dosage:

Makena (autoinjector) is available in solution form for subcutaneous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
275MG/1.1ML (250MG/ML) SOLUTION Prescription SUBCUTANEOUS